Heraeus PALACOS MV pro bone cement recalled for ampoule breakage
Heraeus Medical's PALACOS MV pro bone cement systems (models 5150633 and 5150635) have experienced increased reports of ampoule breakage during use. When ampoules fail to break properly or incompletely, the cement cannot form correctly and cannot be used in surgery.
From the FDA notice · Read the official notice ↗
What to do
- Stop using affected PALACOS MV pro 40 and PALACOS MV pro 80 systems immediately
- Check your inventory for UDI codes 04260102135338 or 04260102135369
- Contact Heraeus Medical or your supplier for instructions on returns or replacements
- Consult your facility's recall protocol before any scheduled procedures using this product
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Brand Name: PALACOS Product Name: PALACOS MV pro 40; PALACOS MV pro 80 Model/Catalog Number: 5150633; 5150635 Software Version: N/A Product Description: Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix). Component: N/A
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
This recall covers 4 products — see all of them.
Details
- Illnesses reported
- None reported
- Manufactured in
- Philipp-Reis-Str. 8, Wehrheim, Germany
- Classification
- Class II
- Recall number
- Z-1083-2026
In the FDA's words
- Description
- Brand Name: PALACOS Product Name: PALACOS MV pro 40; PALACOS MV pro 80 Model/Catalog Number: 5150633; 5150635 Software Version: N/A Product Description: Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix). Component: N/A increase of complaints regarding the breakage of the ampoules within their device systems. An extensive investigation revealed that multiple factors have an impact on the ampoule breakage. An unfortunate combination of these influence factors can lead to unbreakable ampoules. If none or not all ampoules break, the product cannot be used on the patient since no or no appropriate cement dough is formed. Lot Code: UDI-DI: 04260102135338; 04260102135369 Distribution: International distribution in the countries of Aland Islands, Australia, Belgium, Denmark, Finland, Germany, Ireland, Italy, Liechtenstein, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom.
- Hazard
- increase of complaints regarding the breakage of the ampoules within their device systems. An extensive investigation revealed that multiple factors have an impact on the ampoule breakage. An unfortunate combination of these influence factors can lead to unbreakable ampoules. If none or not all ampoules break, the product cannot be used on the patient since no or no appropriate cement dough is formed.
4 products in this recall
PALACOS bone cement recalled for ampoule breakage risk
Heraeus is recalling four PALACOS bone cement products sold in 17 countries outside the US. Some ampoules may not break during mixing, so no usable cement forms and the product cannot be used on a patient. No injuries have been reported.
The agency lists each product separately. Check every one you might have.
- Brand Name: PALACOS Product Name: PALACOS R pro 40; PALACOS R pro 80 Model/Catalog Number: 5081286; 5081287 Software Version: N/A Product Description: Ra…Z-1080-2026
- Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80 Model/Catalog Number: 5081288; 5081289 Software Version: N/A Product Description…Z-1081-2026
- Brand Name: PALACOS Product Name: PALACOS MV+G pro 40; PALACOS MV+G pro 80 Model/Catalog Number: 5081290; 5081291 Software Version: N/A Product Descripti…Z-1082-2026
- Brand Name: PALACOS Product Name: PALACOS MV pro 40; PALACOS MV pro 80 Model/Catalog Number: 5150633; 5150635 Software Version: N/A Product Description:… (this page)Z-1083-2026
More from Heraeus
- Heraeus Medical PALACOS R pro bone cement recalled for monomer liquid leakage risk
ModerateFDAOct 7, 2026